Emmaus Life Sciences Reports 2021 Financial Results and Provides Business Update
Torrance CA, March 31, 2022 - Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported financial results for the year ended December 31, 2021 and an update on recent activities.
|●||March 2022: Announced that the Florida Medicaid Pharmaceutical & Therapeutics Committee has added Endari® to the Florida Medicaid Preferred Drug List, effective April 1, 2022, eliminating the need for prior authorization for Medicaid patients.|
|●||March 2022: Received full marketing authorization for Endari from the United Arab Emirates (U.A.E.) Ministry of Health after a five-month review of the company’s marketing authorization application.|
|●||December 2021: Presented positive transfusion data from a post-hoc analysis of the phase 3 clinical study of Endari, the company's prescription L-glutamine oral powder, in patients with sickle cell disease, at the 63rd American Society of Hematology (ASH) Annual Meeting. Data confirmed that Endari meaningfully reduces both pain crises and hospitalizations.|
|●||November 2021: Announced collaboration with UpScript to offer telehealth solutions to sickle cell disease patients, expanding access to Endari®. The partnership allows patients to see a doctor remotely and receive same-day physician authorization and prescriptions for Endari, which will be delivered directly to their home within just a few days.|
|●||November 2021: Entered into an agreement with Asembia to provide expanded patient and provider support services to simplify access to Endari. Asembia provides a single point of contact for benefits investigation and financial and co-pay assistance, as well as patient and provider education.|
|●||October 2021: Signed an agreement with Kainos Medicine, Inc., granting Emmaus an exclusive license to patent rights, know-how and other intellectual property relating to Kainos' novel IRAK4 inhibitor (KM10544) for the treatment of cancers, including leukemia, lymphoma and solid tumors.|
“Recently, we have made substantial progress in expanding access to Endari for sickle cell disease patients in need,” stated Yutaka Niihara, M.D., M.P.H., Chairman and Chief Executive Officer of Emmaus. “Although our financial results for 2021 were below our expectations, we anticipate that the full roll-out of our new telehealth solution in the coming weeks will improve patient access and efficiency in the delivery of Endari to sickle cell patients throughout the United States. Internationally, we are pleased to have recently received marketing approval of Endari in the U.A.E. and our first major order from our exclusive distributor there. We are actively pursuing additional marketing approvals of Endari to treat the approximately 225,000 sickle cell disease patients throughout the Middle East North Africa (MENA) region and we expect this expanded distribution, along with our telehealth solution, to help generate increased sales of Endari during 2022.”
Dr. Niihara continued, “In addition to our focus on increasing patient access to Endari, we have expanded our clinical pipeline. In particular, we have seen promising results from our ongoing preclinical studies of the IRAK4 inhibitor licensed from Kainos Medicine, Inc. in October 2021, which may prove to be a novel, potential treatment option for hard-to-treat lymphomas such as Waldenström’s Macroglobulinemia with MYD88 mutation. We also eagerly anticipate results from an additional proof-of-concept study of Endari as a treatment for diverticulosis, expected in mid-2022. If positive, we should be able to move directly into a registration trial. The current year is shaping up to be an exciting one for Emmaus and we look forward to providing updates throughout the year.”
Financial and Operating Results
Net Revenues. Net revenues for the year ended December 31, 2021 were $20.6 million, compared to $23.2 million for 2020. Although sales volume as measured by number of boxes of Endari sold held steady compared to 2020, net revenues were adversely affected by somewhat higher and more frequent discounts afforded distributors on bulk pre-orders in 2021 compared to 2020.
Operating Expenses. Total operating expenses for the year were $23.4 million, compared with $21.0 million for 2020. Of the increased expenses, $1.7 million was attributable to increased research and development expenses primarily related to license fees paid to Kainos Medicine, Inc. relating to Kainos’ novel IRAK4 inhibitor in research and development expenses associated with the company’s pilot/phase 1 diverticulosis sub-study in which enrollment was completed in December 2021. The company also incurred a $1.0 million increase in selling expenses resulting from more frequent travel associated with the lifting of COVID-19 related travel restrictions in the U.S. and foreign countries.
Operating Income (Loss). Operating loss for the year ended December 31, 2021 was $6.1 million, compared with operating loss of $32,000 in 2020.
Other Income (Expense). Other expense increased by $10.8 million, or 1,074%, to $9.8 million for the year ended December 31, 2021, compared to other income of $1.0 million in 2020, which included a $7.7 million gain from sale of marketable securities. The company did not realize a similar gain in 2021. The increase in other expense in 2021 included a $3.5 million increase in foreign exchange loss and a $2.0 million increase in change in fair value of conversion feature derivatives, partially offset by a $2.9 million decrease in interest expense.
Net Income (Loss). For the year, the company reported a net loss attributable to common stockholders of $15.9 million, or $0.32 per share, based on approximately 49.3 million weighted average basic and diluted common shares. This compares to net income of $1.4 million, or $0.03 per share, based on approximately 49.0 million weighted average basic and diluted common shares, for 2020. The increased net loss was primarily attributable to the operating loss for the year and increase in other expense discussed above.
Liquidity and Capital Resources. At December 31, 2021, the company had cash and cash equivalents of $2.3 million, compared with $2.5 million at December 31, 2020.
About Emmaus Life Sciences
Emmaus Life Sciences, Inc. is a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease. The company currently markets U.S. Food and Drug Administration approved Endari® (L-glutamine oral powder), indicated to reduce the acute complications of sickle cell disease in adults and children 5 years and older. The company is also engaged in the discovery and development of innovative treatments and therapies for certain rare and orphan diseases as well as those affecting larger populations, such as diverticulosis. For more information, please visit www.emmausmedical.com.
About Endari® (prescription grade L-glutamine oral powder)
Endari®, Emmaus’ prescription grade L-glutamine oral powder, was approved by the FDA in July 2017 for treating sickle cell disease in adult and pediatric patients five years of age and older. Sales of Endari® began in the United States in 2018.
Endari® is indicated to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older.
Important Safety Information
The most common adverse reactions (incidence >10 percent) in clinical studies were constipation, nausea, headache, abdominal pain, cough, pain in extremities, back pain, and chest pain.
Adverse reactions leading to treatment discontinuation included one case each of hypersplenism, abdominal pain, dyspepsia, burning sensation, and hot flash.
The safety and efficacy of Endari in pediatric patients with sickle cell disease younger than five years of age has not been established.
For more information, please see full Prescribing Information of Endari at: www.ENDARIrx.com/PI.
This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding possible increased access to Endari in the U.S. through telemedicine and potential increased sales of Endari following full marketing authorization for Endari in the U.A.E. and, possibly, other countries in the Middle East North Africa region. These forward-looking statements are subject to numerous assumptions, risks and uncertainties which change over time, including uncertainties related to the company’s working capital and ability to carry on its existing operations and obtain needed financing, risks inherent in the commercialization of Endari in the U.S. and abroad, and other factors disclosed in the company’s Annual Report on Form 10-K for 2021 filed with the Securities and Exchange Commission on March 31, 2022, and actual results may differ materially. Such forward-looking statements speak only as of the date they are made, and Emmaus assumes no duty to update them, except as may be required by law.
Emmaus Life Sciences, Inc.
Chief Operating Officer
(310) 214-0065, Ext. 1130
Investor Relations Contact:
Rx Communications Group
(Financial Tables Follow)
Emmaus Life Sciences, Inc.
Condensed Consolidated Statement of Operations and Comprehensive Income (Loss)
(in thousands, except share and per share amounts)
|Year Ended December 31|
|Cost of Goods Sold||3,312||2,248|
|Loss from Operations||(6,128||)||(32||)|
|Total Other Income (Expense)||(9,793||)||1,005|
|Net Income (Loss)||(15,946||)||1,354|
|Comprehensive Income (Loss)||(17,345||)||2,577|
|Earnings (Net Loss) per Share||$||(0.32||)||$||0.03|
|Weighted Average Common Shares Outstanding||49,253,156||48,897,004|
Emmaus Life Sciences, Inc.
Condensed Consolidated Balance Sheets
|As of December 31,|
|Cash and cash equivalents||$||2,279||$||2,487|
|Accounts receivable, net||1,040||198|
|Prepaid expenses and other current assets||1,380||1,485|
|Total Current Assets||9,091||11,257|
|Property and Equipment, net||147||120|
|Equity method investment||17,616||15,925|
|Right of use assets||3,485||4,072|
|Investment in convertible bond||26,100||27,866|
|Liabilities and Stockholders’ Deficit|
|Accounts payable and accrued expenses||$||9,189||$||7,460|
|Conversion feature derivative, notes payable||7,507||--|
|Notes payable, current portion||2,399||4,588|
|Convertible debentures, net of discount||--||5,480|
|Convertible notes payable, net of discount||10,158||--|
|Other current liabilities||7,847||5,854|
|Total Current Liabilities||37,100||23,382|
|Notes payable, less current portion||1,500||222|
|Convertible notes payable, net of discount||3,150||3,150|
|Other long-term liabilities||36,434||37,940|
|Total Liabilities & Stockholders’ Deficit||$||56,734||$||59,536|